This is a MS news story, published by ScienceDaily, that relates primarily to Contineum Therapeutics news.
For more MS news, you can click here:
more MS newsFor more biology news, you can click here:
more biology newsFor more news from ScienceDaily, you can click here:
more news from ScienceDailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about
multiple sclerosis. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest new myelin sheath news, MS patients news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
MS therapiesScienceDaily
•
75% Informative
Multiple sclerosis degrades the protective insulation around nerve cells, leaving their axons, which carry electrical impulses, exposed like bare wires.
Without treatment, it can lead to paralysis, loss of independence and a shortened lifespan.
New therapy targets an elusive receptor on certain cells in the brain that prompts them to mature into myelin-producing oligodendrocytes.
PIPE-307 is being tested in MS patients in Phase II of Phase II .
The drug is being developed by Contineum Therapeutics .
If successful, it could transform how MS is treated.
In 2021 , it passed a Phase I clinical trial, demonstrating its safety.
VR Score
84
Informative language
90
Neutral language
38
Article tone
formal
Language
English
Language complexity
53
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links